Sungyong You

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8862557/publications.pdf

Version: 2024-02-01

135	4,252	147801	123424
papers	citations	31 h-index	61 g-index

147	147	147	7907
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neuron-released oligomeric Î±-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nature Communications, 2013, 4, 1562.	12.8	634
2	Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. Oncotarget, 2015, 6, 11327-11341.	1.8	289
3	Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping. Nature Reviews Cancer, 2011, 11, 708-718.	28.4	241
4	Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy. Proteomics, 2011, 11, 2459-2475.	2.2	211
5	Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Research, 2016, 76, 4948-4958.	0.9	147
6	Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. Nature Communications, 2020, 11, 4489.	12.8	134
7	A novel pathogenic role of the ER chaperone GRP78/BiP in rheumatoid arthritis. Journal of Experimental Medicine, 2012, 209, 871-886.	8.5	128
8	Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy. Cancer Cell, 2021, 39, 1202-1213.e6.	16.8	124
9	MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer. Cancer Research, 2017, 77, 2306-2317.	0.9	119
10	ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nature Medicine, 2018, 24, 1887-1898.	30.7	113
11	Identification of key regulators for the migration and invasion of rheumatoid synoviocytes through a systems approach. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 550-555.	7.1	98
12	Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. Journal of Pathology, 2013, 231, 77-87.	4.5	93
13	Urinary exosomes and proteomics. Mass Spectrometry Reviews, 2011, 30, 1185-1202.	5.4	79
14	Transcription factor NFAT5 promotes macrophage survival in rheumatoid arthritis. Journal of Clinical Investigation, 2017, 127, 954-969.	8.2	76
15	NF-AT5 is a critical regulator of inflammatory arthritis. Arthritis and Rheumatism, 2011, 63, 1843-1852.	6.7	75
16	RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocrine-Related Cancer, 2014, 21, 311-326.	3.1	74
17	Review: The Tumorâ€Like Phenotype of Rheumatoid Synovium: Molecular Profiling and Prospects for Precision Medicine. Arthritis and Rheumatology, 2018, 70, 637-652.	5.6	68
18	Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential. Cancer Research, 2018, 78, 6086-6097.	0.9	49

#	Article	IF	Citations
19	LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Science Translational Medicine, 2020, 12, .	12.4	49
20	Principal network analysis: identification of subnetworks representing major dynamics using gene expression data. Bioinformatics, 2011, 27, 391-398.	4.1	48
21	Î²1-integrin-dependent migration of microglia in response to neuron-released Î±-synuclein. Experimental and Molecular Medicine, 2014, 46, e91-e91.	7.7	48
22	Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes. Scientific Reports, 2015, 5, 12136.	3.3	48
23	MicroRNA-143 and -145 modulate the phenotype of synovial fibroblasts in rheumatoid arthritis. Experimental and Molecular Medicine, 2017, 49, e363-e363.	7.7	48
24	Phospholipids of tumor extracellular vesicles stratify gefitinib-resistant nonsmall cell lung cancer cells from gefitinib-sensitive cells. Proteomics, 2015, 15, 824-835.	2.2	47
25	Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clinical Cancer Research, 2021, 27, 320-329.	7.0	46
26	Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment. Proteomics, 2014, 14, 1845-1856.	2.2	44
27	Genes involved in prostate cancer progression determine MRI visibility. Theranostics, 2018, 8, 1752-1765.	10.0	43
28	Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism. Theranostics, 2018, 8, 4520-4534.	10.0	40
29	IL-6 Receptor Î± Defines Effector Memory CD8+T Cells Producing Th2 Cytokines and Expanding in Asthma. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1383-1394.	5.6	38
30	Comprehensive palmitoylâ€proteomic analysis identifies distinct protein signatures for large and small cancerâ€derived extracellular vesicles. Journal of Extracellular Vesicles, 2020, 9, 1764192.	12.2	37
31	Urinary Metabolite Profiling Combined with Computational Analysis Predicts Interstitial Cystitis-Associated Candidate Biomarkers. Journal of Proteome Research, 2015, 14, 541-548.	3.7	36
32	27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6â€“JAKâ€“STAT3 Signaling in Prostate Cancer Cells. Molecular Cancer Research, 2020, 18, 671-684.	3.4	35
33	Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells. Oncotarget, 2016, 7, 84645-84657.	1.8	33
34	DNA Methylation Regulates the Differential Expression of CX3CR1 on Human IL-7RÎ±low and IL-7RÎ±high Effector Memory CD8+ T Cells with Distinct Migratory Capacities to the Fractalkine. Journal of Immunology, 2015, 195, 2861-2869.	0.8	32
35	The Role of Extracellular Vesicles in Disease Progression and Detection of Hepatocellular Carcinoma. Cancers, 2021, 13, 3076.	3.7	30
36	Urinary Proteome Profile Predictive of Disease Activity in Rheumatoid Arthritis. Journal of Proteome Research, 2014, 13, 5206-5217.	3.7	29

#	Article	IF	Citations
37	SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. Oncotarget, 2015, 6, 44072-44083.	1.8	29
38	GREM1 Is a Key Regulator of Synoviocyte Hyperplasia and Invasiveness. Journal of Rheumatology, 2016, 43, 474-485.	2.0	28
39	A novel machine learning approach reveals latent vascular phenotypes predictive of renal cancer outcome. Scientific Reports, 2017, 7, 13190.	3.3	28
40	Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis. European Urology Open Science, 2020, 20, 37-47.	0.4	27
41	A Systems Approach to Rheumatoid Arthritis. PLoS ONE, 2012, 7, e51508.	2.5	26
42	S-Palmitoylation as a Functional Regulator of Proteins Associated with Cisplatin Resistance in Bladder Cancer. International Journal of Biological Sciences, 2020, 16, 2490-2505.	6.4	26
43	Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells. MAbs, 2014, 6, 340-353.	5.2	25
44	Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2. Oncogene, 2014, 33, 3235-3245.	5.9	25
45	From proteomics toward systems biology: integration of different types of proteomics data into network models. BMB Reports, 2008, 41, 184-193.	2.4	25
46	Integration of proteomic and transcriptomic profiles identifies a novel PDGF-MYC network in human smooth muscle cells. Cell Communication and Signaling, 2014, 12, 44.	6.5	24
47	KRT13 promotes stemness and drives metastasis in breast cancer through a plakoglobin/c-Myc signaling pathway. Breast Cancer Research, 2022, 24, 7.	5.0	23
48	Downregulation of CENPF Remodels Prostate Cancer Cells and Alters Cellular Metabolism. Proteomics, 2019, 19, 1900038.	2.2	22
49	Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. Prostate Cancer and Prostatic Diseases, 2020, 23, 419-428.	3.9	22
50	Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer. Cancers, 2018, 10, 379.	3.7	21
51	Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target. Cancer Letters, 2018, 437, 1-12.	7.2	21
52	TMPRSS2 activity may mediate sex differences in COVID-19 severity. Signal Transduction and Targeted Therapy, 2021, 6, 100.	17.1	21
53	Menthol, a unique urinary volatile compound, is associated with chronic inflammation in interstitial cystitis. Scientific Reports, 2018, 8, 10859.	3.3	20
54	A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Theranostics, 2019, 9, 2812-2826.	10.0	20

#	Article	IF	Citations
55	Transcriptomic analysis of human ILâ€7 receptor alpha^{low} and^{high} effector memory CD8⁺ T cells reveals an ageâ€associated signature linked to influenza vaccine response in older adults. Aging Cell, 2019, 18, e12960.	6.7	20
56	'Omics' Approaches to Understanding Interstitial Cystitis/Painful Bladder Syndrome/Bladder Pain Syndrome. International Neurourology Journal, 2012, 16, 159.	1.2	19
57	Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis. Nature Communications, 2022, 13, 669.	12.8	19
58	Regulation of inside-out Î²1-integrin activation by CDCP1. Oncogene, 2018, 37, 2817-2836.	5.9	17
59	Transcription Factor NFAT5 Promotes Migration and Invasion of Rheumatoid Synoviocytes via Coagulation Factor III and CCL2. Journal of Immunology, 2018, 201, 359-370.	0.8	17
60	Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer. Molecular Therapy, 2022, 30, 485-500.	8.2	17
61	Quantitative proteomic analysis of prostate tissue specimens identifies deregulated protein complexes in primary prostate cancer. Clinical Proteomics, 2019, 16, 15.	2.1	15
62	A comparative study of PCS and PAM50 prostate cancer classification schemes. Prostate Cancer and Prostatic Diseases, 2021, 24, 733-742.	3.9	14
63	Cholesterol-Lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity. Clinical Cancer Research, 2022, 28, 414-424.	7.0	14
64	Alpha-oxoglutarate inhibits the proliferation of immortalized normal bladder epithelial cells via an epigenetic switch involving ARID1A. Scientific Reports, 2018, 8, 4505.	3.3	13
65	Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential. BMC Cancer, 2020, 20, 398.	2.6	13
66	Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells. Cancer Medicine, 2018, 7, 4639-4649.	2.8	12
67	On the Road to Accurate Protein Biomarkers in Prostate Cancer Diagnosis and Prognosis: Current Status and Future Advances. International Journal of Molecular Sciences, 2021, 22, 13537.	4.1	11
68	Transcriptome analysis of wild-type and afsS deletion mutant strains identifies synergistic transcriptional regulator of afsS for a high antibiotic-producing strain of Streptomyces coelicolor A3(2). Applied Microbiology and Biotechnology, 2018, 102, 3243-3253.	3.6	9
69	Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-12.	3.0	9
70	A Synthetic Form of Frizzled 8-Associated Antiproliferative Factor Enhances p53 Stability through USP2a and MDM2. PLoS ONE, 2012, 7, e50392.	2.5	8
71	Stromal androgen and hedgehog signaling regulates stem cell niches in pubertal prostate development. Development (Cambridge), 2021, 148, .	2.5	8
72	Circulating Tumor Cellâ€“Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissueâ€Based Messenger RNA Profiling Into a Noninvasive Setting. Liver Transplantation, 2022, 28, 200-214.	2.4	8

#	Article	IF	Citations
73	Quantitative Proteomic Analysis Reveals Caffeineâ€Perturbed Proteomic Profiles in Normal Bladder Epithelial Cells. Proteomics, 2018, 18, e1800190.	2.2	7
74	Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate. Oncogene, 2019, 38, 6507-6520.	5.9	7
75	IL-7 receptor alpha defines heterogeneity and signature of human effector memory CD8+ T cells in high dimensional analysis. Cellular Immunology, 2020, 355, 104155.	3.0	7
76	Circulating tumor cells: A step toward precision medicine in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1179-1190.	2.8	7
77	Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. European Urology Open Science, 2022, 40, 19-26.	0.4	7
78	Identification of Caveolin-1 as an Invasion-Associated Gene in Liver Cancer Cells Using Dendron-Coated DNA Microarrays. Applied Biochemistry and Biotechnology, 2017, 182, 1276-1289.	2.9	6
79	Pioglitazone Alters the Proteomes of Normal Bladder Epithelial Cells but Shows No Tumorigenic Effects. International Neurourology Journal, 2020, 24, 29-40.	1.2	6
80	Comprehensive data resources and analytical tools for pathological association of aminoacyl tRNA synthetases with cancer. Database: the Journal of Biological Databases and Curation, 2015, 2015, bav022-bav022.	3.0	4
81	Covalent Chemistryâ€Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma. Advanced Materials Technologies, 2021, 6, 2001056.	5.8	4
82	NUAK family kinase 2 is a novel therapeutic target for prostate cancer. Molecular Carcinogenesis, 2022, 61, 334-345.	2.7	4
83	Differential perturbation of the interstitial cystitis-associated genes of bladder and urethra in rat model. Cell Cycle, 2017, 16, 749-758.	2.6	3
84	A Systems Approach to Prostate Cancer Classificationâ€”Response. Cancer Research, 2017, 77, 7133-7135.	0.9	2
85	Alendronate-induced Perturbation of the Bone Proteome and Microenvironmental Pathophysiology. International Journal of Medical Sciences, 2021, 18, 3261-3270.	2.5	2
86	miR-1227 Targets SEC23A to Regulate the Shedding of Large Extracellular Vesicles. Cancers, 2021, 13, 5850.	3.7	2
87	BoxCar and shotgun proteomic analyses reveal molecular networks regulated by UBR5 in prostate cancer. Proteomics, 2022, 22, e2100172.	2.2	2
88	Prediction of the Immune Phenotypes of Bladder Cancer Patients for Precision Oncology. IEEE Open Journal of Engineering in Medicine and Biology, 2022, 3, 47-57.	2.3	2
89	An integrative approach for high-throughput screening and characterization of transcriptional regulators in Streptomyces coelicolor. Pure and Applied Chemistry, 2010, 82, 57-67.	1.9	1
90	LB-S&T-10 THREE INTRINSIC SUBTYPES OF PROSTATE CANCER WITH DISTINCT PATHWAY ACTIVATION PROFILES DIFFER IN PROGNOSIS AND TREATMENT RESPONSE. Journal of Urology, 2016, 195, .	0.4	1

#	Article	IF	Citations
91	Remote focusing multifocal plane microscopy for the imaging of 3D single molecule dynamics with cellular context. , 2017, 10070, .		1
92	WALNUTS for POWER: A Protocol for the Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Randomized Controlled Trial. Current Developments in Nutrition, 2020, 4, nzaa044_015.	0.3	1
93	Nuclear size of circulating tumor cells in advanced prostate cancer to reveal a potential biomarker for clinical outcomes and androgen receptor indifference.. Journal of Clinical Oncology, 2021, 39, 167-167.	1.6	1
94	ONECUT2 Is a Targetable Master Regulator of Lethal Prostate Cancer That Suppresses the Androgen Axis. SSRN Electronic Journal, 0, , .	0.4	1
95	Abstract 5474: The formin, DIAPH3, regulates response to MT stabilizing drugs in prostate and breast cancer. Cancer Research, 2014, 74, 5474-5474.	0.9	1
96	Development of a circulating tumor cell-based RNA classifier for patients with castration-resistant prostate cancer: CTC-PCS/PAM50.. Journal of Clinical Oncology, 2020, 38, e17509-e17509.	1.6	1
97	Prostate cancer CTC-RNA Assay: A new method for contemporary genomics and precision medicine via liquid biopsy.. Journal of Clinical Oncology, 2020, 38, 170-170.	1.6	1
98	Early detection of primary liver cancer using plasma cellâ€free DNA fragmentomics: Do all the pieces come together?. Hepatology, 2022, 76, 289-291.	7.3	1
99	Extracellular vesicle-based assay for detecting metastases and dynamic monitoring of prostate cancer.. Journal of Clinical Oncology, 2022, 40, 182-182.	1.6	1
100	An extracellular vesicle-based assay for noninvasive detection of metastases and monitoring prostate cancer.. Journal of Clinical Oncology, 2022, 40, e17004-e17004.	1.6	1
101	1871 AN EGFR SUBCELLULAR TRAFFICKING NETWORK IN CHEMORESISTANT BLADDER CANCER. Journal of Urology, 2013, 189, .	0.4	0
102	511 NFAT5 AS A TRANSCRIPTIONAL MEDIATOR OF MESENCHYMAL-AMOEBOID TRANSITION INDUCED BY DIAPH3 LOSS IN PROSTATE CANCER. Journal of Urology, 2013, 189, .	0.4	0
103	32 A SIGNALING NETWORKING EVOKED BY THE INTERSTITIAL CYSTITIS-ASSOCIATED FRIZZLED 8-RELATED ANTIPROLIFERATIVE FACTOR. Journal of Urology, 2013, 189, .	0.4	0
104	512 MICROVESICLES SHED FROM DIAPH3-SILENCED, AMOEBOID PROSTATE CANCER CELLS ENHANCE GROWTH OF OTHER TUMOR CELLS AND SUPPRESS PROLIFERATION OF IMMUNE CELLS. Journal of Urology, 2013, 189, .	0.4	0
105	Systems Approaches to Autoimmune Diseases. , 2016, , 135-149.		0
106	Imaging of Three-Dimensional Single Molecule Dynamics in their Cellular Context. Biophysical Journal, 2017, 112, 294a.	0.5	0
107	MP87-11 INTRINSIC PROSTATE CANCER SUBTYPES DETERMINEDÂIN DIAGNOSTIC PROSTATE BIOPSIES OFÂMEN WITH METASTATIC DISEASE RESEMBLE CASTRATION-RESISTANT PROSTATE CANCER METASTASES. Journal of Urology, 2017, 197, .	0.4	0
108	A morphological subset of circulating tumor cells in advanced prostate cancer reveals a potential biomarker for clinical outcomes.. Journal of Clinical Oncology, 2021, 39, e17008-e17008.	1.6	0

#	Article	IF	Citations
109	Abstract 764: Circulating tumor cell-based mRNA scoring system for prognostication of hepatocellular carcinoma - Translating HCC tissue-based mRNA profiling into a non-invasive setting. , 2021, , .		0
110	A novel pathogenic role of the ER chaperone GRP78/BiP in rheumatoid arthritis. Journal of Cell Biology, 2012, 197, i2-i2.	5.2	0
111	Abstract 4868: Large oncosomes are internalized and functionally modulate transcription factors in recipient cells. , 2014, , .		0
112	Abstract A1-49: Prostate cancer classification using a transcriptome atlas. , 2015, , .		0
113	Abstract B1-63: Prostate cancer classification using a transcriptome atlas. , 2015, , .		0
114	Abstract 1856: Transcriptional regulation of the UDP-glucuronosyltransferases (UGTs) by SAFB1 and SAFB2: Strategy to reduce DHT levels in prostate cancer cells. , 2016, , .		0
115	Abstract 1502: Three intrinsic subtypes of prostate cancer with distinct pathway activation profiles differ in prognosis and treatment response. , 2016, , .		0
116	NanoVelcro CTC purification systems for expressional analysis of circulating tumor cells from prostate cancer patients.. Journal of Clinical Oncology, 2018, 36, 295-295.	1.6	0
117	Dynamic variations in gene expressions of circulating tumor cells in metastatic castration-resistant prostate cancer patients in response to androgen receptor signaling inhibitors.. Journal of Clinical Oncology, 2018, 36, e17063-e17063.	1.6	0
118	Abstract 2269: Transcription factor relationships associated with androgen-deprivation therapy response and metastatic progression in prostate cancer. , 2018, , .		0
119	Abstract 1578: NanoVelcro CTC Purification Systems for expressional analysis of circulating tumor cells from prostate cancer patients. , 2018, , .		0
120	Abstract 2694: Receptor-interacting protein kinase 2 promotes prostate cancer progression by activating the MAX:MYC pathway. , 2018, , .		0
121	Abstract 5208: Monocyte-produced Chitinase-3-like 1 is a driver of metastatic behavior in prostate cancer patients. , 2018, , .		0
122	Abstract A047: ONECUT2 is a targetable master regulator of aggressive variants of castration-resistant prostate cancer. , 2018, , .		0
123	Abstract B086: Monocytes-produced Chitinase-3-like 1 is a driver of metastatic behavior in advanced prostate cancer patients. , 2018, , .		0
124	Radiogenomic characterization of multifocal prostate cancer.. Journal of Clinical Oncology, 2019, 37, 126-126.	1.6	0
125	A circulating tumor cell RNA assay for dynamic assessment of androgen receptor signaling inhibitors sensitivity in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 157-157.	1.6	0
126	A circulating tumor cell specific RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5059-5059.	1.6	0

#	Article	IF	Citations
127	Abstract 3590: Mechanisms and inhibition RIOK2 for obesity-driven prostate cancer. , 2019, , .		0
128	Abstract 453: A circulating tumor cell assay for dynamic assessment of drug sensitivity in metastatic castration-resistant prostate cancer. , 2019, , .		0
129	ONECUT2 as a new therapeutic target in androgen receptor-indifferent prostate cancer. Translational Cancer Research, 2019, 8, 2677-2679.	1.0	0
130	Association of very small nuclear circulating tumor cell (vsnCTC) with clinical outcomes in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2020, 38, 168-168.	1.6	0
131	Defining the monocyte subset transcriptional signature associated with progression during androgen-target therapy in prostate cancer patients.. Journal of Clinical Oncology, 2020, 38, 157-157.	1.6	0
132	Loss of CDCP1 triggers FAK activation in detached prostate cancer cells. American Journal of Clinical and Experimental Urology, 2021, 9, 350-366.	0.4	0
133	Scaffold attachment factor B1 regulates androgen degradation pathways in prostate cancer. American Journal of Clinical and Experimental Urology, 2021, 9, 337-349.	0.4	0
134	Characterizing molecular subtypes of high-risk nonmuscle-invasive bladder cancer in African American patients.. Journal of Clinical Oncology, 2022, 40, 527-527.	1.6	0
135	HIF-pathway genes prognostic for progression-free and overall survival in metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology, 2022, 40, 370-370.	1.6	0